SCHEMBL1444069

SCHEMBL1444069

COC(=O)c1ccc(OCc2ccccc2F)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.74
PARP15 Q460N3 2/20 0.69
PARP10 Q53GL7 2/20 0.69
PARP14 Q460N5 1/20 0.69
MAPT P10636 4/20 0.59
RAB9A P51151 4/20 0.59
ALDH1A1 P00352 2/20 0.57
KMT2A Q03164 2/20 0.57
SCN3A Q9NY46 1/20 0.55
LPAR1 Q92633 1/20 0.55
LPAR5 Q9H1C0 1/20 0.55
SCN9A Q15858 1/20 0.55
NPC1 O15118 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
LMNA P02545 1/20 0.53
MEN1 O00255 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14505835 0.87 MAOB (0.59) MAOBPARP15PARP10PARP14MAPT
SCHEMBL16507526 0.86 LPAR1 (0.80) MAOBPARP15PARP10PARP14LPAR1
SCHEMBL2087950 0.85 MAOB (1.00) MAOBPARP15PARP10PARP14RAB9A
SCHEMBL6687945 0.84 MAPT (0.58) MAOBPARP15PARP10PARP14MAPT
SCHEMBL711371 0.83 MAOB (0.56) MAOBPARP15PARP10PARP14MAPT
SCHEMBL1444784 0.83 MAOB (0.75) MAOBPARP15PARP10PARP14RAB9A
SCHEMBL14505834 0.82 GCK (0.57) MAOBPARP15PARP10PARP14RAB9A
SCHEMBL10396449 0.82 MAOB (0.74) MAOBMAPTRAB9AKMT2ANPC1
SCHEMBL20883219 0.82 PARP10 (1.00) MAOBPARP15PARP10PARP14RAB9A
SCHEMBL14505836 0.82 MAOB (0.51) MAOBPARP15PARP10PARP14MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2477964-B1 Process for preparing alpha-carboxamide derivatives CONVERGENCE PHARMACEUTICALS (GB) 2015-02-11 EP disclosed
US-8759542-B2 Process for preparing alpha-carboxamide derivatives Convergence Pharmaceuticals Limited (GB) 2014-06-24 US disclosed
US-8759542-B2 Process for preparing alpha-carboxamide derivatives Convergence Pharmaceuticals Limited (GB) 2014-06-24 US disclosed
US-8759542-B2 Process for preparing alpha-carboxamide derivatives Convergence Pharmaceuticals Limited (GB) 2014-06-24 US disclosed
US-20120226053-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES Convergence Pharmaceuticals Limited 2012-09-06 US disclosed
US-20120226053-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES Convergence Pharmaceuticals Limited 2012-09-06 US disclosed
US-20120226053-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES Convergence Pharmaceuticals Limited 2012-09-06 US disclosed
EP-2477964-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES Convergence Pharmaceuticals Limited (GB) 2012-07-25 EP disclosed
WO-2011029762-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES Convergence Pharmaceuticals Limited (GB) 2011-03-17 WO disclosed
WO-2011029762-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES Convergence Pharmaceuticals Limited (GB) 2011-03-17 WO disclosed
US-4910206-A Endotoxin induced lung injury SANDOZ PHARMACEUTICALS CORP. (US) 1990-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120226053-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE DERIVATIVES CBR1, CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAOB 2874/4885PARP15 1714/4885PARP10 1647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.